155 related articles for article (PubMed ID: 15482392)
1. Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia.
Ren XS; Lee AF; Huang YH; Hamed A; Herz L; Miller DR; Kazis LE
J Clin Pharm Ther; 2004 Oct; 29(5):471-81. PubMed ID: 15482392
[TBL] [Abstract][Full Text] [Related]
2. Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents.
Ren XS; Qian S; Lee AF; Herz L; Miller DR; Kazis LE
J Clin Pharm Ther; 2006 Feb; 31(1):57-65. PubMed ID: 16476121
[TBL] [Abstract][Full Text] [Related]
3. Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.
Yu W; Ren XS; Lee AF; Herz L; Huang YH; Kazis LE
Pharmacoeconomics; 2006; 24(12):1233-48. PubMed ID: 17129077
[TBL] [Abstract][Full Text] [Related]
4. A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia.
Cooper D; Moisan J; Abdous B; Grégoire JP
Can J Clin Pharmacol; 2008; 15(3):e385-97. PubMed ID: 18953083
[TBL] [Abstract][Full Text] [Related]
5. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration.
Ritchie CW; Chiu E; Harrigan S; MacFarlane S; Mastwyk M; Halliday G; Hustig H; Hall K; Hassett A; O'Connor DW; Opie J; Nagalingam V; Snowdon J; Ames D
Int J Geriatr Psychiatry; 2006 Feb; 21(2):171-9. PubMed ID: 16416458
[TBL] [Abstract][Full Text] [Related]
8. Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia.
Cooper D; Moisan J; Gaudet M; Abdous B; Grégoire JP
Can J Psychiatry; 2005 Dec; 50(14):901-8. PubMed ID: 16494259
[TBL] [Abstract][Full Text] [Related]
9. [Functional status and quality of life in Latin American outpatients with schizophrenia treated with atypical or typical antipsychotics: outcomes of the 12 months schizophrenia outpatient health outcomes (IC-SOHO) Study].
Rovner J; Assunção S; Gargoloff P; Ibarra HS; Gasca JA; Fournais EL; Adan P; Andrades NJ; Dyachkova Y
Vertex; 2005; 16(63):332-41. PubMed ID: 16220148
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
Gasquet I; Haro JM; Novick D; Edgell ET; Kennedy L; Lepine JP;
Int Clin Psychopharmacol; 2005 Jul; 20(4):199-205. PubMed ID: 15933480
[TBL] [Abstract][Full Text] [Related]
11. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
[TBL] [Abstract][Full Text] [Related]
13. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.
Smith RC; Lindenmayer JP; Davis JM; Kelly E; Viviano TF; Cornwell J; Hu Q; Khan A; Vaidhyanathaswamy S
J Clin Psychiatry; 2009 Nov; 70(11):1501-13. PubMed ID: 19814947
[TBL] [Abstract][Full Text] [Related]
14. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.
van Nimwegen LJ; de Haan L; van Beveren NJ; van der Helm M; van den Brink W; Linszen D
Can J Psychiatry; 2008 Jun; 53(6):400-5. PubMed ID: 18616861
[TBL] [Abstract][Full Text] [Related]
15. Patients' opinions of olanzapine and risperidone following long-term treatment: results from a cross-sectional survey.
McGrath BM; Tempier RP
Pharmacopsychiatry; 2005 Jul; 38(4):147-57. PubMed ID: 16025416
[TBL] [Abstract][Full Text] [Related]
16. LORETA functional imaging in antipsychotic-naive and olanzapine-, clozapine- and risperidone-treated patients with schizophrenia.
Tislerova B; Brunovsky M; Horacek J; Novak T; Kopecek M; Mohr P; Krajca V
Neuropsychobiology; 2008; 58(1):1-10. PubMed ID: 18781085
[TBL] [Abstract][Full Text] [Related]
17. Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting.
Kilzieh N; Todd-Stenberg JA; Kennedy A; Wood AE; Tapp AM
J Clin Psychopharmacol; 2008 Feb; 28(1):74-7. PubMed ID: 18204345
[TBL] [Abstract][Full Text] [Related]
18. Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications.
Savina I; Beninger RJ
Schizophr Res; 2007 Aug; 94(1-3):128-38. PubMed ID: 17560766
[TBL] [Abstract][Full Text] [Related]
19. Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting.
Akkaya C; Sarandol A; Cangur S; Kirli S
Hum Psychopharmacol; 2007 Dec; 22(8):515-28. PubMed ID: 17868197
[TBL] [Abstract][Full Text] [Related]
20. [Prolactin secretion disturbances in schizophrenic patients treated with 2nd generation antipsychotics--risperidone and olanzapine].
Wyszogrodzka-Kucharska A; Kunert-Radek J; Rabe-Jabłońska J
Psychiatr Pol; 2005; 39(6):1143-55. PubMed ID: 16526181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
